Effet des vaccins & Corruption
IHU-MI - 11 mai 2021
Pr Didier Raoult, Directeur de l’IHU Méditerranée Infection :
En pratique, les vaccins protègent à 50% pas plus.
Parmi les vaccinés, il y a moins d’hospitalisations ; mais, il n’y a pas moins de morts.
L’idée du vaccin fait pour protéger le reste de la population est fausse dans ce cas.
À Marseille, 46 patients ont fait un covid dans la semaine qui a suivi l’injection du vaccin.
La probabilité, si on vous vaccine pas, que vous ayez dans la semaine un covid est moins importante que si on vous vaccine.
Analyse et preuve de la corruption et de ses dangers.
Liens vers articles et sources :
https://www.justice.gov/opa/pr/gile…
https://www.ft.com/content/216d2e3e…
https://www.reuters.com/article/us-…
https://en.wikipedia.org/wiki/GSK_C…
https://www.nejm.org/doi/pdf/10.105…
Sauvegarde : http://mai68.org/spip2/IMG/pdf/nejm…
https://www.thelancet.com/action/sh…
Sauvegarde : http://mai68.org/spip2/IMG/pdf/PIIS…
https://www.nejm.org/doi/pdf/10.105…
Sauvegarde : http://mai68.org/spip2/IMG/pdf/nejm…
- - - - - -
Sauvegarde du 1er lien :
Gilead Agrees To Pay $97 Million To Resolve Alleged False Claims Act Liability For Paying Kickbacks
https://www.justice.gov/opa/pr/gile…
Wednesday, September 23, 2020
Pharmaceutical company Gilead Sciences, Inc. (Gilead), based in Foster City, California, has agreed to pay $97 million to resolve claims that it violated the False Claims Act by illegally using a foundation as a conduit to pay the copays of thousands of Medicare patients taking Gilead’s pulmonary arterial hypertension drug, Letairis, the Justice Department announced today.
“This settlement demonstrates the government’s commitment to hold accountable companies that pay illegal kickbacks, whether directly or through a third party,” said Acting Assistant Attorney General Jeffrey Bossert Clark of the Department of Justice’s Civil Division. “We will not allow permit pharmaceutical manufacturers to set unaffordable drug prices while circumventing important cost-control mechanisms within the Medicare program.”
“Like its competitors, Actelion and United Therapeutics, Gilead used data from CVC that it knew it should not have, and effectively set up a proprietary fund within CVC to cover the co-pays of just its own drug,” said U.S. Attorney Andrew E. Lelling for the District of Massachusetts. “Such conduct not only violates the anti-kickback statute, it also undermines the Medicare program’s co-pay structure, which Congress created as a safeguard against inflated drug prices. During the period covered by today’s settlement, Gilead raised the price of Letairis by over seven times the rate of overall inflation in the United States.”
“When pharmaceutical companies deceitfully employ the charitable donation process as an instrument to subsidize copays for their own drugs, it subverts a critical safeguard against the excessive inflation of drug costs,” said Phillip M. Coyne, Special Agent in Charge, Office of the Inspector General of the Department of Health and Human Service’s Boston Regional Office. “Manipulation of this process threatens the integrity of our federal healthcare system, disregarding the American taxpayer who ultimately bears the cost. As such, we remain vigilantly focused on confronting this type of conduct and will continue our aggressive enforcement in this area.”
“Health care fraud costs our country tens of billions of dollars each year because of unscrupulous schemes like the one Gilead orchestrated that dangled kickbacks disguised as copay assistance in front of Medicare patients,” said Joseph R. Bonavolonta, Special Agent in Charge of the Federal Bureau of Investigations, Boston Division. “Today’s $97 million settlement ensures Gilead pays for defrauding a government insurance program and reaffirms the FBI’s resolve to pursue investigations and exhaust all efforts to uncover these schemes.”
When a Medicare beneficiary obtains a prescription drug covered by Medicare, the beneficiary may be required to make a partial payment, which may take the form of a copayment, coinsurance, or a deductible (collectively “copays”). Congress included copay requirements in the Medicare program, in part, to serve as a check on health care costs, including the prices that pharmaceutical manufacturers can demand for their drugs.
Under the Anti-Kickback Statute, a pharmaceutical company is prohibited from offering or paying, directly or indirectly, any remuneration — which includes money or any other thing of value — to induce Medicare patients to purchase the company’s drugs. This prohibition extends to the payment of patients’ copay obligations.
Gilead sells Letairis, which is approved for treatment of pulmonary arterial hypertension. The government alleged that Gilead used a foundation, which claims 501©(3) status for tax purposes, as a conduit to pay the copay obligations of thousands of Medicare patients taking Letairis and to induce those patients to purchase Letairis, because it knew that the prices Gilead set for Letairis could otherwise pose a barrier to those purchases. From 2007 through 2010, Gilead made payments to the foundation, which, in turn, used those funds to pay copays of patients prescribed Letairis. The government alleged that Gilead routinely obtained data from the foundation detailing how much the foundation had spent for patients on Letairis ; it then used this information to decide how much to pay to the foundation and to confirm that its payments were sufficient to cover the copays of only patients taking Letairis. The government also alleged that, to generate revenue from Medicare and induce purchases of Letairis, Gilead referred Medicare patients to the foundation, which resulted in claims to Medicare to cover the cost of Letairis.
The government’s resolution of this matter illustrates the government’s emphasis on combating healthcare fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).
The investigation was conducted by the Civil Division’s Commercial Litigation Branch and the U.S. Attorney’s Office for the District of Massachusetts, in conjunction with the Department of Health and Human Services, Office of Inspector General and the Federal Bureau of Investigation.
The claims resolved by the settlement are allegations only ; there has been no determination of liability.
- - - - - -
Sauvegarde du 2e lien :
Pfizer fined for decade of bribery
https://www.ft.com/content/216d2e3e…
- - - - - -
Sauvegarde du 3e lien :
AstraZeneca to pay $5.52 million to resolve SEC foreign bribery case
https://www.reuters.com/article/us-…
August 31, 2016 12:33 AM Updated 5 years ago
By Nate Raymond
(Reuters) - U.S. regulators said on Tuesday that AstraZeneca Plc AZN.L will pay $5.52 million to resolve a foreign bribery probe into improper payments by its sales and marketing staff to state-employed healthcare officials in China and Russia.
The U.S. Securities and Exchange Commission detailed the settlement with the London-based drug company in an order instituting an administrative proceeding arising out of violations of provisions in the Foreign Corrupt Practices Act.
AstraZeneca, which cooperated with the probe, neither admitted nor denied wrongdoing. In a statement, it said the U.S. Justice Department has meanwhile closed a related foreign bribery investigation.
“We are pleased to have resolution of these matters,” the company said.
Neither the SEC nor Justice Department responded to requests for comment.
The SEC said that AstraZeneca through at least 2010 failed to devise and maintain a system of internal accounting controls relating to its subsidiaries’ interactions with Chinese and Russian government officials.
Sales and marketing staff in those countries as far back as 2005 provided gifts, conference support, travel, cash and other benefits to the state-employed healthcare providers to buy or prescribe the company’s products, the SEC said.
The company’s Chinese subsidiary also paid healthcare providers speaker fees, sometimes for “totally fabricated” engagements, and in 2008, paid local officials to get reductions or dismissals of proposed financial sanctions it faced, the SEC said.
AstraZeneca also falsely recorded the improper payments in China and Russia as bona fide business expenses, the SEC said.
The regulator said AstraZeneca cooperated with the probe, which factored into the size of the penalty that was assessed against it.
The SEC also said the company has been addressing deficiencies in its compliance program and taking various steps with employees involved in the case, resulting in some being reassigned or fired.
Reporting by Nate Raymond in New York ; editing by Alan Crosby, G Crosse
- - - - - -
Sauvegarde du 4e lien :
GSK China scandal
https://en.wikipedia.org/wiki/GSK_C…
The GSK China scandal was an imbroglio where the China branch of the global drugmaker GlaxoSmithKline (GSK) pleaded guilty to paying bribes to doctors and hospitals to promote the company’s products in China.
The scandal started with sex tapes of the company’s China head, Mark Reilly and his Chinese girlfriend at a Shanghai department, which were sent to several senior executives of the company. The company’s investigations into the sex tapes led to imprisonment of the paid investigator Peter Humphrey and his wife Yu Yingzeng in China, a country which has an opaque judicial system with a 99% conviction rate, on allegations that they had breached privacy law. Humphrey and his wife maintain their innocence and Humphrey claims he was tortured and denied medical treatment due to his refusal to confess to trumped up charges.
After the trial in Changsha in September 2014, the company apologized to the Chinese people, and paid one of the biggest fines in Chinese history worth ¥3bn (£300m ; €350m ; $490m). 4 executives of the company, including Mark Reilly, the only foreign citizens involved, were sentenced. Reilly received a suspended sentence and was also deported from China. The UK Serious Fraud Office concluded their investigation in 2019 after finding insufficient evidence[1]
The scandal started with sex tapes of the company’s China head, Mark Reilly and his Chinese girlfriend at a Shanghai department, which were sent to several senior executives of the company. The company’s investigations into the sex tapes led to imprisonment of the paid investigator Peter Humphrey and his wife Yu Yingzeng in China on allegations they had breached privacy law. Humphrey alleges he was tortured and denied medical care due to his refusal to confess.
After the trial in Changsha in September 2014, the company apologized to the Chinese people, and paid one of the biggest fines in Chinese history worth ¥3bn (£300m ; €350m ; $490m).[2][3] 4 executives of the company, including Mark Reilly, the only foreign citizens involved, were convicted. Reilly received a suspended sentence and was deported from China. In 2019 the UK Securities Fraud Office closed the investigation due to insufficient evidence.[4]
La suite au lien ci-dessus
RSS 2.0